237 related articles for article (PubMed ID: 1516631)
1. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
Loutrari H; Kokla A; Tzartos SJ
Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
[TBL] [Abstract][Full Text] [Related]
2. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
Tzartos SJ; Sophianos D; Efthimiadis A
J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
[TBL] [Abstract][Full Text] [Related]
3. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci.
Protopapadakis E; Kokla A; Tzartos SJ; Mamalaki A
Eur J Immunol; 2005 Jun; 35(6):1960-8. PubMed ID: 15915538
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
Biesecker G; Gomez CM
J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
[TBL] [Abstract][Full Text] [Related]
6. Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.
Sterz R; Hohlfeld R; Rajki K; Kaul M; Heininger K; Peper K; Toyka KV
Muscle Nerve; 1986 May; 9(4):306-12. PubMed ID: 2423869
[TBL] [Abstract][Full Text] [Related]
7. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
Meinl E; Klinkert WE; Wekerle H
Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
[TBL] [Abstract][Full Text] [Related]
8. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis.
Graus Y; Meng F; Vincent A; van Breda Vriesman P; de Baets M
J Immunol; 1995 Jun; 154(12):6382-96. PubMed ID: 7539019
[TBL] [Abstract][Full Text] [Related]
9. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
Zoda T; Yeh TM; Krolick KA
J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
[TBL] [Abstract][Full Text] [Related]
10. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.
Agius MA; Richman DP
J Immunol; 1986 Oct; 137(7):2195-8. PubMed ID: 3489757
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
[TBL] [Abstract][Full Text] [Related]
12. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
Krolick KA; Yeh TM; Edlund SA
Cell Immunol; 1996 Aug; 172(1):10-20. PubMed ID: 8806801
[TBL] [Abstract][Full Text] [Related]
13. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane.
Corey AL; Richman DP; Agius MA; Wollmann RL
J Immunol; 1987 May; 138(10):3269-75. PubMed ID: 3494763
[TBL] [Abstract][Full Text] [Related]
14. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis.
Asher O; Kues WA; Witzemann V; Tzartos SJ; Fuchs S; Souroujon MC
J Immunol; 1993 Dec; 151(11):6442-50. PubMed ID: 8245477
[TBL] [Abstract][Full Text] [Related]
15. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor.
Tzartos S; Hochschwender S; Vasquez P; Lindstrom J
J Neuroimmunol; 1987 Jun; 15(2):185-94. PubMed ID: 3495549
[TBL] [Abstract][Full Text] [Related]
16. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
17. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
Gomez CM; Richman DP
J Immunol; 1985 Jul; 135(1):234-41. PubMed ID: 3873489
[TBL] [Abstract][Full Text] [Related]
19. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
20. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
